[go: up one dir, main page]

MX2015010971A - Derivado novedoso de pirazol. - Google Patents

Derivado novedoso de pirazol.

Info

Publication number
MX2015010971A
MX2015010971A MX2015010971A MX2015010971A MX2015010971A MX 2015010971 A MX2015010971 A MX 2015010971A MX 2015010971 A MX2015010971 A MX 2015010971A MX 2015010971 A MX2015010971 A MX 2015010971A MX 2015010971 A MX2015010971 A MX 2015010971A
Authority
MX
Mexico
Prior art keywords
compound
salt
solvate
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MX2015010971A
Other languages
English (en)
Inventor
Akihiro Okano
Fumihiko Saitoh
Muneyoshi Makabe
Kouki Ogawa
Original Assignee
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharm Co Ltd filed Critical Mochida Pharm Co Ltd
Publication of MX2015010971A publication Critical patent/MX2015010971A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se ha deseado desarrollar una composición farmacéutica, que se utilice en agentes para prevenir y/o tratar diversas enfermedades relacionó con la PDE10 (por ejemplo un trastorno mental y un trastorno neurodegenerativo). La presente invención proporciona: compuestos que tienen un efecto inhibidor de la PDE10, en particular, compuestos que tienen una estructura de la amida del ácido 4-heteroarilpirazol-5-carboxílico representada por la siguiente fórmula (I), o sus sales farmacéuticamente aceptables, o sus solvatos; las composiciones farmacéuticas que comprenden, como ingredientes activos, los compuestos, o su sales farmacéuticamente aceptables, o sus solvatos; y uso médico de los compuestos, o sus sales farmacéuticamente las aceptables, o sus solvatos. (ver Fórmula).
MX2015010971A 2013-02-27 2014-02-26 Derivado novedoso de pirazol. MX2015010971A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013038030 2013-02-27
PCT/JP2014/054773 WO2014133046A1 (ja) 2013-02-27 2014-02-26 新規ピラゾール誘導体

Publications (1)

Publication Number Publication Date
MX2015010971A true MX2015010971A (es) 2015-10-26

Family

ID=51428306

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015010971A MX2015010971A (es) 2013-02-27 2014-02-26 Derivado novedoso de pirazol.

Country Status (17)

Country Link
US (6) US8980889B2 (es)
EP (1) EP2963037B1 (es)
JP (2) JP5642323B1 (es)
KR (1) KR102169426B1 (es)
CN (3) CN106957317B (es)
AU (1) AU2014221799B2 (es)
BR (1) BR112015020302B1 (es)
CA (1) CA2902781C (es)
ES (1) ES2723876T3 (es)
HU (1) HUE043059T2 (es)
MX (1) MX2015010971A (es)
NZ (1) NZ708593A (es)
PT (1) PT2963037T (es)
RU (1) RU2682247C2 (es)
TR (1) TR201904614T4 (es)
WO (1) WO2014133046A1 (es)
ZA (1) ZA201505397B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ708593A (en) * 2013-02-27 2018-01-26 Mochida Pharm Co Ltd Novel pyrazole derivative
CN107074845A (zh) * 2014-07-30 2017-08-18 持田制药株式会社 吡唑衍生物的制造方法
KR20170032329A (ko) 2014-07-30 2017-03-22 모찌다 세이야쿠 가부시끼가이샤 피라졸 유도체의 제조 방법
ES2764660T3 (es) 2014-12-16 2020-06-04 Axovant Sciences Gmbh Compuestos de amida de quinuclidina sustituida geminal como agonistas de receptores alfa-7 nicotínicos de acetilcolina
UA118822C2 (uk) * 2015-05-29 2019-03-11 Вуксі Фортуне Фармасьютікал Ко., Лтд Інгібітор янус-кінази
MX2017016231A (es) 2015-06-10 2018-11-29 Axovant Sciences Gmbh Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina.
HK1253295A1 (zh) 2015-08-12 2019-06-14 Axovant Sciences Gmbh 作为7-烟碱乙酰胆碱受体的激动剂的偕取代的氨基苯并异恶唑化合物
CN106554351A (zh) * 2015-09-30 2017-04-05 持田制药株式会社 吡唑衍生物的制备方法
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
SMT202200369T1 (it) 2015-11-19 2022-11-18 Incyte Corp Composti eterociclici come immunomodulatori
WO2017090716A1 (ja) * 2015-11-26 2017-06-01 持田製薬株式会社 ピラゾール誘導体の結晶
JP6745594B2 (ja) * 2015-11-26 2020-08-26 持田製薬株式会社 ピラゾール誘導体の塩の結晶
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
SG10202005790VA (en) 2015-12-22 2020-07-29 Incyte Corp Heterocyclic compounds as immunomodulators
WO2017143036A1 (en) * 2016-02-16 2017-08-24 President And Fellows Of Harvard College Modulators of ms4a activity
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
TW201808902A (zh) 2016-05-26 2018-03-16 美商英塞特公司 作為免疫調節劑之雜環化合物
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
CN107525877B (zh) * 2016-06-20 2021-08-03 重庆医药工业研究院有限责任公司 一种采用液相色谱法分离测定依匹哌唑及其杂质的方法
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
CN106317059B (zh) * 2016-08-19 2018-10-12 成都理工大学 一种大麻素受体2(cb2)激动剂
CN106317043B (zh) * 2016-08-19 2018-11-02 成都理工大学 一种大麻素受体2激动剂
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
PL3558990T3 (pl) 2016-12-22 2022-12-19 Incyte Corporation Pochodne tetrahydroimidazo[4,5-c]pirydyny jako induktory internalizacji pd-l1
MA47099A (fr) 2016-12-22 2021-05-12 Incyte Corp Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs
MX391981B (es) 2016-12-22 2025-03-21 Incyte Corp Derivados de benzooxazol como inmunomoduladores.
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
US10846592B2 (en) * 2017-08-09 2020-11-24 Carl Steven Gold Organic learning
UA128453C2 (uk) 2018-03-30 2024-07-17 Інсайт Корпорейшн Гетероциклічні сполуки як імуномодулятори
PL3790877T3 (pl) 2018-05-11 2023-06-12 Incyte Corporation Pochodne tetrahydroimidazo[4,5-c]pirydyny jako immunomodulatory pd-l1
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
PL3894529T3 (pl) * 2018-12-11 2023-05-29 Unilever Ip Holdings B.V. Kompozycje do kondycjonowania tkanin
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
CN115175734B (zh) 2019-09-30 2024-04-19 因赛特公司 作为免疫调节剂的吡啶并[3,2-d]嘧啶化合物
CA3160131A1 (en) 2019-11-11 2021-05-20 Incyte Corporation Salts and crystalline forms of a pd-1/pd-l1 inhibitor
PE20231073A1 (es) * 2020-04-29 2023-07-17 Relay Therapeutics Inc Inhibidores de pi3k y metodos de uso de los mismos
KR20250171459A (ko) * 2020-06-05 2025-12-08 노에마 파르마 아게 투렛 증후군의 치료를 위한 포스포디에스테라제 10 억제제의 용도
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
MX2023005362A (es) 2020-11-06 2023-06-22 Incyte Corp Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo.
WO2022146462A1 (en) * 2020-12-31 2022-07-07 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
US11229644B1 (en) 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
CN114524808B (zh) * 2022-02-21 2023-10-24 深圳市儿童医院 一种吡唑衍生物及其作为pde10抑制剂的用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
IL149106A0 (en) 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
DE10130167A1 (de) 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
EP1678161B1 (en) 2003-10-09 2009-12-30 Millennium Pharmaceuticals, Inc. Thioether-substituted benzamides as inhibitors of factor xa
JP2007523152A (ja) 2004-02-18 2007-08-16 ファイザー・プロダクツ・インク キナゾリンおよびイソキノリンのテトラヒドロイソキノリニル誘導体
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
EA012211B1 (ru) 2005-01-07 2009-08-28 Пфайзер Продактс Инк. Гетероароматические соединения хинолинов и их применение в качестве ингибиторов pde10
TW200640511A (en) 2005-01-12 2006-12-01 Steris Inc Integrated decontamination system
JP5475234B2 (ja) 2005-01-21 2014-04-16 アステックス・セラピューティクス・リミテッド 医薬化合物
CA2647266A1 (en) 2006-04-18 2007-10-25 Boehringer Ingelheim International Gmbh Process for making cytokine inhibiting compounds containing 4- and 5- imidazolyl rings and the intermediates thereof
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
EP2272510A1 (en) 2009-07-06 2011-01-12 Institut Pasteur Inhibitors of the proline racemase of trypanosoma cruzi
KR101250923B1 (ko) 2010-08-05 2013-04-04 포항공과대학교 산학협력단 홍합 접착 단백질 또는 이의 변이체에 음이온성 고분자로 형성된 코아세르베이트
CN102548991B (zh) * 2009-09-24 2015-03-25 霍夫曼-拉罗奇有限公司 作为磷酸二酯酶10a抑制剂的咪唑并吡啶或咪唑并嘧啶衍生物
US8410117B2 (en) * 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
US8703768B2 (en) 2010-06-09 2014-04-22 Hoffmann-La Roche Inc. Nitrogen containing heteroaryl compounds
WO2012009009A2 (en) * 2010-07-14 2012-01-19 Addex Pharma S.A. Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US8349824B2 (en) 2010-12-07 2013-01-08 Hoffmann-La Roche Inc. Triazolopyridine compounds
JP2014122161A (ja) * 2011-03-31 2014-07-03 Astellas Pharma Inc ピラゾール化合物
NZ708593A (en) * 2013-02-27 2018-01-26 Mochida Pharm Co Ltd Novel pyrazole derivative

Also Published As

Publication number Publication date
ES2723876T3 (es) 2019-09-03
JP5642323B1 (ja) 2014-12-17
TR201904614T4 (en) 2019-05-21
CA2902781A1 (en) 2014-09-04
EP2963037B1 (en) 2019-03-27
US8980888B2 (en) 2015-03-17
AU2014221799B2 (en) 2017-09-28
US9458157B2 (en) 2016-10-04
NZ708593A (en) 2018-01-26
US20140378448A1 (en) 2014-12-25
KR20150120383A (ko) 2015-10-27
US9440970B2 (en) 2016-09-13
RU2015135891A (ru) 2017-03-31
US20160347751A1 (en) 2016-12-01
CN105189493A (zh) 2015-12-23
JP5816353B2 (ja) 2015-11-18
EP2963037A4 (en) 2016-08-03
CN105189493B (zh) 2017-04-12
CA2902781C (en) 2020-12-29
RU2682247C2 (ru) 2019-03-18
KR102169426B1 (ko) 2020-10-23
US20150133448A1 (en) 2015-05-14
JP2015042659A (ja) 2015-03-05
AU2014221799A1 (en) 2015-09-17
US20150132327A1 (en) 2015-05-14
BR112015020302A2 (pt) 2017-07-18
EP2963037A1 (en) 2016-01-06
US9453015B2 (en) 2016-09-27
US9777000B2 (en) 2017-10-03
US8980889B2 (en) 2015-03-17
CN106957317B (zh) 2019-12-31
HUE043059T2 (hu) 2019-07-29
CN107011343A (zh) 2017-08-04
BR112015020302B1 (pt) 2023-04-18
WO2014133046A1 (ja) 2014-09-04
US20150166536A1 (en) 2015-06-18
US20140378447A1 (en) 2014-12-25
CN106957317A (zh) 2017-07-18
ZA201505397B (en) 2016-12-21
JPWO2014133046A1 (ja) 2017-02-02
PT2963037T (pt) 2019-04-23

Similar Documents

Publication Publication Date Title
MX2015010971A (es) Derivado novedoso de pirazol.
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
MX2016013529A (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
MX391180B (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo
PH12016500467A1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
IN2014MN01754A (es)
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
DK2840080T3 (da) Nitrogenholdig heterocyklisk forbindelse eller salt deraf
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
WO2011107608A8 (en) Heterocyclic amides as rock inhibitors
EP4309735A3 (en) Pharmaceutical composition of s-ketamine hydrochloride
MX2016006667A (es) Derivados de pirrolo-pirrolona y su uso como inhibidores.
MX357780B (es) Derivados policíclicos, proceso para su preparación y su uso farmacéutico.
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
PH12015502365A1 (en) Bace1 inhibitors
PH12018500378B1 (en) Novel annelated phenoxyacetamides
MX2016004934A (es) Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
WO2015082590A3 (en) Bis-mmf derivatives
IN2015DN02109A (es)
WO2014106826A3 (en) Anthracycline analogue and uses thereof
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
IN2014MN02433A (es)
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions

Legal Events

Date Code Title Description
FG Grant or registration